Ascelia Pharma AB
STO:ACE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ascelia Pharma AB
Revenue
Ascelia Pharma AB
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ascelia Pharma AB
STO:ACE
|
Revenue
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Revenue
kr1.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Revenue
kr1.2B
|
CAGR 3-Years
53%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Revenue
kr3.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
23%
|
CAGR 10-Years
17%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Revenue
kr28.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
24%
|
|
|
BioArctic AB
STO:BIOA B
|
Revenue
kr2B
|
CAGR 3-Years
106%
|
CAGR 5-Years
100%
|
CAGR 10-Years
N/A
|
|
Ascelia Pharma AB
Glance View
Ascelia Pharma AB engages in the research and development of pharmaceutical products for the treatment of cancer and cancer-related diseases. The company is headquartered in Malmo, Skane. The company went IPO on 2019-03-13. The firm identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The firm's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. The company has completed phase I of clinical studies.
See Also
What is Ascelia Pharma AB's Revenue?
Revenue
0
SEK
Based on the financial report for Dec 31, 2025, Ascelia Pharma AB's Revenue amounts to 0 SEK.
